Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Rulemaking On Price Disclosures In DTC Ads Supported In Senate-Passed Bill

Executive Summary

US congressional action comes as HHS forwards proposed rule on enhancing drug pricing transparency to Office of Management and Budget for review.

You may also be interested in...



PhRMA’s Defensive Move On DTC Ads: Putting Drug List Prices ‘In Context’

Member companies’ direct-to-consumer TV ads will direct patients to information about drug costs – including list price, estimated out-of-pocket costs for the drug, and availability of financial assistance – under a voluntary program that takes effect in April 2019; initiative falls short of mandatory list price disclosures proposed by Trump Administration.

DTC Ad Price Disclosure Provision Stripped From US Funding Bill

Even though measure was blocked in Congress, it may still advance through regulation.

Pfizer Expects Rebate Reform By HHS Will Extend Quickly To Private Market

CEO Ian Read offers view of what’s ahead in US drug pricing reform based on his recent meeting with President Trump at the White House.

Related Content

Topics

UsernamePublicRestriction

Register

PS123752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel